The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

April 12, 2021

Kerry A. Rogers, MD, discusses the next steps with the triplet combination of obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia.

March 12, 2021

Seema A. Bhat, MD, discusses updates from key studies and highlighted the promise of novel PI3K inhibitors in chronic lymphocytic leukemia.

February 15, 2021

Narendranath Epperla, MD, MS, expands on findings from the L-MIND trial in DLBCL, as well as the significance of selinexor and other options in the pipeline.

January 22, 2021

David Cohn, MD, discusses how to approach COVID-19 vaccination in patients with cancer.

December 16, 2020

Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of leukemias and lymphomas.

December 09, 2020

Timothy M. Pawlik, MD, PhD, MPH, discusses advances in the management of patients with metastatic colorectal cancer with liver metastases.

October 21, 2020

Seema A. Bhat, MD, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.

October 19, 2020

Seema A. Bhat, MD, discusses the approval of acalabrutinib in chronic lymphocytic leukemia based on data from the phase 3 ELEVATE-TN trial.

October 15, 2020

Seema A. Bhat, MD, discusses the potential for time-limited combination regimens in chronic lymphocytic leukemia.

October 14, 2020

Seema A. Bhat, MD, spotlights the advances that have been made with BTK inhibitors in chronic lymphocytic leukemia, shares emerging approaches under exploration, and forecasts where the field is headed.

October 14, 2020

Seema A. Bhat, MD, emerging targeted therapies in chronic lymphocytic leukemia.

October 12, 2020

Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.

October 05, 2020

Seema A. Bhat, MD, discusses the combination of ibrutinib plus fludarabine, cyclophosphamide, and rituximab in young patients with treatment-naïve CLL.

October 02, 2020

Seema A. Bhat, MD, hematologist, discusses the role of targeted therapies in chronic lymphocytic leukemia.

September 23, 2020

Kami J. Maddocks, MD, discusses ongoing sequencing challenges in diffuse large B-cell lymphoma.

September 22, 2020

Kami J. Maddocks, MD, discusses remaining challenges in treating patients with follicular lymphoma.

September 16, 2020

Kami J. Maddocks, MD, discusses unanswered questions with BTK inhibitors in B-cell malignancies.

September 15, 2020

Kami J. Maddocks, MD, discusses the tolerability and promise of tafasitamab in combination with lenalidomide in relapsed or refractory DLBCL.

September 14, 2020

Jennifer Woyach, MD, discusses clinical trials examining novel triplet regimens in chronic lymphocytic leukemia.

September 14, 2020

Kami J. Maddocks, MD, discusses the role of tazemetostat in patients with EZH2-mutant follicular lymphoma.